Evidence map›Paper›PMID 32089710›Full record

ArticleStem cells international2020

Screening Genes Promoting Exit from Naive Pluripotency Based on Genome-Scale CRISPR-Cas9 Knockout.

Bin Yang, Junqi Kuang, Chuman Wu, Wenyi Zhou, Shuoji Zhu, Haodong Jiang, Ziwei Zhai, Yue Wu, Junwei Peng, Nanbo Liu and 5 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Bin Yang *The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China.ORCID https://orcid.org/0000-0003-1776-0703
Junqi Kuang *Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China.ORCID https://orcid.org/0000-0003-2681-7580
Chuman Wu *Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China.ORCID https://orcid.org/0000-0002-9520-4107
Wenyi Zhou *Guangdong Institute of Cardiovascular Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China.ORCID https://orcid.org/0000-0002-9958-3458
Shuoji Zhu *Guangdong Institute of Cardiovascular Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China.ORCID https://orcid.org/0000-0001-7845-5919
Haodong JiangGuangdong Institute of Cardiovascular Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China.ORCID https://orcid.org/0000-0002-3248-5597
Ziwei ZhaiGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China.ORCID https://orcid.org/0000-0002-8892-5491
Yue WuSchool of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, China.ORCID https://orcid.org/0000-0002-2242-9903
Junwei PengSchool of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, China.ORCID https://orcid.org/0000-0002-2324-5575
Nanbo LiuGuangdong Institute of Cardiovascular Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China.ORCID https://orcid.org/0000-0003-1461-7725
Haiyan HuThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China.ORCID https://orcid.org/0000-0002-2131-6472
Nasser Moussa IdeGuangdong Institute of Cardiovascular Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China.ORCID https://orcid.org/0000-0002-2670-6496
Ruiping ChenDepartment of Cardiothoracic Surgery of East Division, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.ORCID https://orcid.org/0000-0002-7504-3633
Mingyi ZhaoDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.ORCID https://orcid.org/0000-0002-2884-0736
Ping ZhuThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China.ORCID https://orcid.org/0000-0002-4276-9593
Guangdong Academy of Medical Sciences · CNChinese Academy of Sciences · CNSouth China University of Technology · CNCentral South University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two of the main problems of stem cell and regenerative medicine are the exit of pluripotency and differentiation to functional cells or tissues. The answer to these two problems holds great value in the clinical translation of stem cell as well as regenerative medicine research. Although piling researches have revealed the truth about pluripotency maintenance, the mechanisms underlying pluripotent cell self-renewal, proliferation, and differentiation into specific cell lineages or tissues are yet to be defined. To this end, we took full advantage of a novel technology, namely, the genome-scale CRISPR-Cas9 knockout (GeCKO). As an effective way of introducing targeted loss-of-function mutations at specific sites in the genome, GeCKO is able to screen in an unbiased manner for key genes that promote exit from pluripotency in mouse embryonic stem cells (mESCs) for the first time. In this study, we successfully established a model based on GeCKO to screen the key genes in pluripotency withdrawal. Our strategies included lentiviral package and infection technology, lenti-Cas9 gene knockout technology, shRNA gene knockdown technology, next-generation sequencing, model-based analysis of genome-scale CRISPR-Cas9 knockout (MAGeCK analysis), GO analysis, and other methods. Our findings provide a novel approach for large-scale screening of genes involved in pluripotency exit and offer an entry point for cell fate regulation research.

Identifiers

PMID32089710
PMCPMC7023212
OpenAlexW3004200533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.